Evidence map›Paper›PMID 23363784›Full record

ArticleAging2012

Potential anti-aging agents suppress the level of constitutive mTOR- and DNA damage- signaling.

H Dorota Halicka, Hong Zhao, Jiangwei Li, Yong-Syu Lee, Tze-Chen Hsieh, Joseph M Wu, Zbigniew Darzynkiewicz

Open access · hybridAbstract read
In one paragraph

Article in Aging, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers.

0numbers the graph read from it
0cells of the map it votes in
60citing papers in PubMed
5.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

60 citing papers in PubMed, 93 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Should metformin remain the first-line therapy for treatment of type 2 diabetes?Therapeutic advances in endocrinology and metabolism · 2021
    Review
  7. Genome-Protecting Compounds as Potential Geroprotectors.International journal of molecular sciences · 2020
    Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Of Cytometry, Stem Cells and Fountain of Youth.Stem cell reviews and reports · 2017
    Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

H Dorota HalickaBrander Cancer Research Institute, Department of Pathology, New York Medical College, Valhalla, NY 10595, USA.
Hong Zhao
Jiangwei Li
Yong-Syu Lee
Tze-Chen Hsieh
Joseph M Wu
Zbigniew Darzynkiewicz
New York Medical College · US

Funding

PROBES FOR FLOW CYTOMETRYR01CA028704 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI DARZYNKIEWICZ, ZBIGNIEW · 1985 to 2014
$6.0M
FACSAria II Cell SorterS10RR026548 · NCRR · NEW YORK MEDICAL COLLEGE · PI DARZYNKIEWICZ, ZBIGNIEW · 2010 to 2010
$500k
Cancer Research UKNCI NIH HHS CA RO1 28704NCI NIH HHS R01 CA028704NCRR NIH HHS S10 RR026548PHS HHS 1 S10 RRO26548-1
6 · The paper itself

Abstract

Two different mechanisms are considered to be the primary cause of aging. Cumulative DNA damage caused by reactive oxygen species (ROS), the by-products of oxidative phosphorylation, is one of these mechanisms (ROS concept). Constitutive stimulation of mitogen- and nutrient-sensing mTOR/S6 signaling is the second mechanism (TOR concept). The flow- and laser scanning- cytometric methods were developed to measure the level of the constitutive DNA damage/ROS- as well as of mTOR/S6- signaling in individual cells. Specifically, persistent activation of ATM and expression of γH2AX in untreated cells appears to report constitutive DNA damage induced by endogenous ROS. The level of phosphorylation of Ser235/236-ribosomal protein (RP), of Ser2448-mTOR and of Ser65-4EBP1, informs on constitutive signaling along the mTOR/S6 pathway. Potential gero-suppressive agents rapamycin, metformin, 2-deoxyglucose, berberine, resveratrol, vitamin D3 and aspirin, all decreased the level of constitutive DNA damage signaling as seen by the reduced expression of γH2AX in proliferating A549, TK6, WI-38 cells and in mitogenically stimulated human lymphocytes. They all also decreased the level of intracellular ROS and mitochondrial trans-membrane potential ΔΨm, the marker of mitochondrial energizing as well as reduced phosphorylation of mTOR, RP-S6 and 4EBP1. The most effective was rapamycin. Although the primary target of each on these agents may be different the data are consistent with the downstream mechanism in which the decline in mTOR/S6K signaling and translation rate is coupled with a decrease in oxidative phosphorylation, (revealed by ΔΨm) that leads to reduction of ROS and oxidative DNA damage. The decreased rate of translation induced by these agents may slow down cells hypertrophy and alleviate other features of cell aging/senescence. Reduction of oxidative DNA damage may lower predisposition to neoplastic transformation which otherwise may result from errors in repair of DNA sites coding for oncogenes or tumor suppressor genes. The data suggest that combined assessment of constitutive γH2AX expression, mitochondrial activity (ROS, ΔΨm) and mTOR signaling provides an adequate gamut of cell responses to evaluate effectiveness of gero-suppressive agents.

Indexed as

Adaptor Proteins, Signal TransducingAspirinAtaxia Telangiectasia Mutated ProteinsBerberineCell Cycle ProteinsCell Line, TumorCellular SenescenceCholecalciferolDeoxyglucoseDNA-Binding ProteinsDNA DamageDown-RegulationEnzyme ActivationFlow CytometryHistonesHumansAdaptor Proteins, Signal TransducingAspirinAtaxia Telangiectasia Mutated ProteinsATM protein, humanBerberineCell Cycle ProteinsCholecalciferolDeoxyglucoseDNA-Binding ProteinsEIF4EBP1 protein, humanH2AX protein, humanHistonesMetforminMTOR protein, humanPhosphoproteinsProtein Serine-Threonine KinasesReactive Oxygen SpeciesResveratrolRibosomal Protein S6 KinasesSirolimusStilbenesTOR Serine-Threonine KinasesTumor Suppressor Proteins

Identifiers

PMID23363784
PMCPMC3615161
OpenAlexW1703681292

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.